Discussion about this post

User's avatar
William J. Maggio's avatar

John, "the cost of checking them went down" is the line that sums up the whole issue. Your first question, who sees every piece of FDA correspondence and who decides whether it's disclosure-relevant, is a decision-rights question before it's a legal one. In a lot of companies, regulatory affairs and securities counsel probably each assume the other owns that judgment. How are boards reacting so far? Are audit committees asking to see the intake process itself, or still waiting for the first SEC letter?

Ready for more?